TEL (translocation-Ets-leukemia or ETV6) was originally identified at the breakpoint of the t(5;12) in patients with chronic myelomonocytic leukemia (1). Chromosomal rearrangements that disrupt TEL lead to a variety of myeloid and lymphoid leukemias, and the proteins fused to TEL can be divided into two broad categories: protein tyrosine kinases or transcription factors. In t(5;12) and t(9;12) the N terminus of TEL is fused to platelet-derived growth factor ␤ or the tyrosine kinase ABL, respectively (1, 2). The Pointed domain located within the N terminus of TEL induces dimerization and subsequent activation of the tyrosine kinases (3-5). In these cases, aberrant regulation of the kinase activity of the fusion proteins is a contributing factor to leukemogenesis.
TEL (translocation-Ets-leukemia or ETV6) was originally identified at the breakpoint of the t(5;12) in patients with chronic myelomonocytic leukemia (1) . Chromosomal rearrangements that disrupt TEL lead to a variety of myeloid and lymphoid leukemias, and the proteins fused to TEL can be divided into two broad categories: protein tyrosine kinases or transcription factors. In t(5;12) and t(9;12) the N terminus of TEL is fused to platelet-derived growth factor ␤ or the tyrosine kinase ABL, respectively (1, 2) . The Pointed domain located within the N terminus of TEL induces dimerization and subsequent activation of the tyrosine kinases (3) (4) (5) . In these cases, aberrant regulation of the kinase activity of the fusion proteins is a contributing factor to leukemogenesis.
On the other hand, fusions of TEL with transcription factors can either retain or eliminate the DNA binding activity of TEL. The t (12;22) fuses the transcription factor MN1 to the C-terminal DNA binding domain of TEL, which converts TEL from a repressor to an activator (6, 7) . Alternatively, in 25% of pediatric acute lymphoid leukemias the t(12;21) fuses the Nterminal Pointed domain and repressor domains of TEL to nearly all of the AML1 1 transcription factor (8, 9) . The TEL/ AML1 fusion protein loses the DNA binding activity of TEL and functions as a constitutive inhibitor of AML1-dependent gene targets (10, 11) . In addition, in 90% of patients with t(12;21) the second allele of TEL is deleted (12) (13) (14) . Loss of heterozygosity of the TEL allele is also observed in other leukemias and some solid tumors (15) (16) (17) (18) . This loss of heterozygosity suggests a role for TEL as a tumor suppressor.
Over 20 mammalian ETS family members have been identified, and they participate in the regulation of cellular adhesion, proliferation, apoptosis, and differentiation (19 -22) . TEL is a widely expressed and essential gene. Targeted disruptions of both Tel alleles in mice resulted in early embryonic lethality, suggesting a role for TEL in multiple developmental pathways (23) . These mice have a severe defect in the developing vascular network of the yolk sac, and in chimeric mice the TEL-null embryonic cells failed to contribute to adult bone marrow (23, 24) . TEL heterodimerizes with a closely related family member, TEL2 or TEL B, but in contrast to TEL, the expression of TEL2 is variable among tissues (25) (26) (27) . Therefore, TEL is hypothesized to have a non-redundant role in either migration or homing of hematopoietic progenitors.
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The forced expression of TEL has growth inhibitory activity, and we observed increased apoptosis of TEL-expressing NIH 3T3 cells that was exacerbated when the cells were cultured in low serum concentrations. A key regulatory point in the apoptotic pathway in response to serum deprivation is the ratio of pro-and anti-apoptotic BCL-2 family members. One anti-apoptotic member, Bcl-X L , contains multiple potential ets factor binding sites (EBS) within its transcriptional control regions (37) . Therefore, we investigated TEL-mediated regulation of Bcl-X L expression and its effect on cell survival.
MATERIALS AND METHODS

Plasmids-
The cytomegalovirus (CMV)-based pCMV5 expression constructs (TEL wild-type, TEL K99R, and TEL⌬ETS) used have been described elsewhere (10, 38) . The pBabe retroviral constructs TEL wild-type (WT) and TEL⌬ETS have been described elsewhere (36) . A 1-kb EcoRI fragment containing the mouse Bcl-X L cDNA was isolated from pW3L-Bcl-X and was subcloned into the EcoRI site of the murine stem cell virus internal ribosome entry site green fluorescent protein retroviral vector. The proper orientation was confirmed with a restriction digest. The Ϫ2361-luc reporter gene plasmid was described previously (39) . The Ϫ876-luc reporter gene plasmid was constructed by PCR amplification of the Bcl-X promoter region from Jurkat genomic DNA with the following primers: 5Ј-GCTAGCTTGAACCCCATTGAGAAGT-CCC-3Ј and 5Ј-AAGCTTTCTCGTCTCTGGTTAGTGATTC-3Ј (Ϫ876 and Ϫ61 relative to the start ATG in Exon 2). The primers had flanking restriction enzyme sites, NheI and HindIII (shown in bold). The PCR fragment was subcloned into the pGL2 basic luciferase plasmid (Promega, Madison, WI). The reporter plasmid Ϫ793-luc, Ϫ565-luc, and Ϫ436-luc were made by PCR amplification of the Ϫ876-luc plasmid with the following 5Ј primers: 5Ј-CCCGCTCGAGCAAAAACCAACTAAATC-CATAC-3Ј, 5Ј-CAATCTCGAGTGCCGGGTCGCATGATCC-3Ј, or 5Ј-CAATCTCGAGGCACCTGCCTGCCTTTGC-3Ј (respectively) and the 3Ј primer 5Ј-GATCAAGCTTCTAAGATCCAAAGCCAAGAT-3Ј (Ϫ84 relative to the start ATG of Exon 2). The primers had flanking restriction enzyme sites, XhoI and HindIII (shown in bold), and the PCR products were digested and then ligated into pGL2 basic luciferase plasmid. These plasmids were verified by sequencing reactions. The RSV Renilla plasmid (Promega, Madison, WI) was used as a control for transfection efficiency.
Cell Culture and Infections-NIH 3T3 cells were maintained in DMEM-CS (DMEM (BioWhittaker, Walkersville, MD) containing 10% calf bovine serum (Hyclone, Logan, UT) and 2 mM L-glutamine). Retroviral packaging NX cells were maintained in DMEM-FBS (DMEM containing 10% fetal bovine serum (Sigma) and 2 mM L-glutamine). Stably infected 3T3 cells were generated as described elsewhere (36) with the following modification: 100-cm 2 plates containing 60 -70% confluent cells were transfected with 5 g of DNA and 8 l of LipofectAMINE 2000 (Invitrogen). At least three independent batches of stably infected NIH 3T3 cells were used for analysis, and similar results were obtained. Heterozygous BCL-X L mice were mated to generate BCL-X L wild-type and knockout littermate embryos (40) . Pregnant mothers were sacrificed at E12, and mouse embryonic fibroblasts were plated in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 units of penicillin/streptomycin per ml, and non-essential amino acids (BioWhittaker, Walkersville, MD). Mouse embryonic fibroblasts were cultured for 10 -12 passages before being immortalized on a standard 3T3 protocol and switched to DMEM-CS (41) .
Transfections and Transcription Assays-NIH 3T3 were transfected as follows: 2 ϫ 10 5 cells were plated per well in 6-well plates. The cells were transfected the next day with 6 l of Superfect reagent (Qiagen, Valencia, CA), 1 g of reporter plasmid, 200 g of internal control plasmid, 50 ng of either pCMV5 empty vector or TEL (WT, ⌬ETS, or K99R) cDNA pCMV5 plasmid, and 250 ng of pCMV5. Cells were harvested 44 to 48 h post-transfection. The cells were washed with PBS and lysed in 150 l of passive lysis buffer (Promega, Madison, WI). Luciferase activities were determined from 20-l aliquots of lysate according to the manufacturer's instructions for the Promega Dual Luciferase Assay kit. The firefly luciferase assays were then normalized with respect to Renilla luciferase activity. Experiments were performed in triplicate and repeated to confirm results.
Cell Viability Assays, RNA Analysis, and Western Blots-Stably infected NIH 3T3 cells or BCL-X L wild-type, heterozygous, or null 3T3 cells were plated at a density of 5 ϫ 10 4 cells per well into 6-well plates in triplicate. Twelve h after plating the cells were rinsed once with PBS, and DMEM containing 0.1% serum was added. Cells were harvested at the times indicated in the figure legends. The numbers of live and dead cells were determined using trypan blue exclusion. The 6-well plates were pre-treated with either 0.05 M HCL or 2 g/cm 2 collagen type IV (BD Biosciences) for 4 h and rinsed extensively with PBS prior to the plating of NIH 3T3 cells. Total RNA was extracted from 10 7 stably infected NIH 3T3 cells using the Promega RNA Mini kit. Ten g of RNA was separated by electrophoresis on a 2.5 M formaldehyde-1% agarose gel and then transferred to Hybond Nϩ membrane (Amersham Biosciences) with 20ϫ SSC and cross-linked using the Stratagene 1800 UV cross-linker. Blots were hybridized with the indicated [␣-
32 P]dATPlabeled cDNA probes (Random Priming Kit; Stratagene, La Jolla, CA) according to the Rapid-hyb (Amersham Biosciences) protocol. Blots were then washed in 2ϫ SSC/0.1% SDS at room temperature for 20 min, followed by two washes in 0.1ϫ SSC/0.1% SDS at 65 o for 15 min. Blots were exposed to film for visualization. Cellular extracts were prepared by trypsinizing cells from 100-mm dishes, washing two times with PBS, and then lysing with PBS containing 0.5% Triton, 0.5% SDS, 0.5% deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 8.5 g/ml aprotinin. One hundred g of protein were separated by SDS-PAGE and then transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA). The membrane was blocked in 5% milk-Tris-buffered saline with 0.2% Tween 20, probed with the following primary antibodies: actin (Sigma), Bcl-X L M125 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), GAPDH (Novus Biologicals, Littleton, CO), and mouse BCL-2 3F11 (BD Biosciences) and peroxidase-conjugated secondary antibodies anti-mouse IgG, anti-rabbit IgG (Sigma), or goat anti-hamster, followed by detections with enhanced chemiluminescence (Pierce).
Microscopy and Immunofluorescence-Stably infected NIH 3T3 cells were plated on coverslips in 10% serum containing DMEM overnight. The cells were then rinsed twice with PBS, and they were grown in either 10 or 0.1% serum-containing media for 24 h. The cells were fixed in 3.7% formaldehyde solution, extracted in 0.5% Triton X-100, and stained with 5 ng/ml Hoescht dye for 5 min. The images were visualized using a Zeiss Axiopot microscope using 40ϫ 1.4 oil immersion objectives. The paxillin immunostaining was performed as described previously (14) . Briefly, the cells were fixed in 3.7% formaldehyde solution, extracted in 0.5% Triton X-100, and stained. Focal adhesions were detected with anti-paxillin antibodies. Immunostaining was visualized with rhodamine-conjugated donkey anti-mouse (Chemicon, Temecula, CA) and fluorescein isothiocyanate-conjugated donkey anti-rabbit antibodies (Chemicon, Temecula, CA) using epi-fluorescence microscopy (Olympus BX60). Images were recorded onto T-Max 400 film (Eastman Kodak Co., Rochester, NY).
Chromatin Immunoprecipitation-The following procedure was modified from the Upstate ChIPs Assay protocol and is described briefly. NIH 3T3 cells were treated with 1% formaldehyde/PBS, lysed, and sonicated to generate fragments between 500 and 1000 bp. The extracts were immunoprecipitated with either a HA (Covance, Princeton, NJ) or an N-terminal TEL-specific antisera and washed extensively. The protein-DNA cross-linking was reversed, and the DNA was eluted. PCR was performed with the following primers: 5Ј-TCCCTTAGAACCCG-GACTCAGACCTTCA-3Ј and 5Ј-GCTCCCGGTTGCTCTGAGACATT-TT-3Ј, which encompass Ϫ250 to ϩ22 of the murine Bcl-X promoter (271-nt product); 5Ј-ACCCATACCTCCGGGAGAGTTCTCC-3Ј and 5Ј-ATCTATCTCCGGCGACAGCAAGCAGGTA-3Ј, which encompass Ϫ759 to Ϫ402 of the ms Bcl-X promoter (357-bp product); 5Ј-TGTGGTTCTG-CTGGGCTCACTCTTCAGT-3Ј and 5Ј-TTAGGGTCCCACCAACAAGA-CAGGCTCT-3Ј, which flank Exon 3 of Bcl-X L (373 nt); and 5Ј-CACAC-GTGTATATTAGGTTGCCTGCCC-3Ј and 5Ј-CACGTAGCCTGTTCGT-AGCAGACAGCC-3Ј, located within the ETO-2 gene (279 nt).
RESULTS
TEL Induces Apoptosis-Expression of TEL in Ras-transformed NIH 3T3 cells caused cell aggregation and decreased cell growth (33) (34) (35) (36) . Alterations in cell growth can be attributed to a slowing of the cell cycle or increased cell death. Although TEL expression caused an increase in the number of cells in the G 1 phase of the cell cycle in one cell type (34), we did not observe any reproducible change in the cell cycle profiles of cells expressing TEL, including B-cells, NIH 3T3 cells, or Rastransformed NIH 3T3 cells plated at low density and assayed prior to aggregation (see Ref. 36 , and data not shown). This information suggested that enforced expression of TEL may trigger apoptosis, which would be consistent with its purported action as a tumor suppressor (12, 17, 42) .
To test whether TEL expression induced apoptosis, NIH 3T3 cells were infected with recombinant retroviruses expressing wild-type TEL or an inactive mutant of TEL that contains a small deletion within the DNA binding (ETS) domain (pBabe, TEL, or TEL⌬ETS, respectively). The cells were fixed, and the chromosomal DNA was stained with Hoescht dye to detect the presence of micronuclei that are characteristic of the nuclear blebbing that occurs in cells undergoing apoptosis. TEL expression caused little or no increase in the number of apoptotic cells when grown in 10% serum (Fig. 1A, upper panel) . However, these stably infected cultures were selected while growing in 10% serum, and therefore, these cells were selected for a level of TEL that allows for normal growth under these conditions. To circumvent this problem, we cultured the cells in media containing only 0.1% serum for 24 h. Under these conditions, the majority of the control cells arrest in the G 1 phase of the cell cycle and survive for several days with a modest level of apoptosis (Fig. 1, A and B, and data not shown). By contrast, there was a marked increase in the percent of micronuclei present in cells expressing TEL (Fig. 1, A and B) .
To extend these observations we measured cell viability at various times after changing the media to low serum. Cells were plated in triplicate and cultured in high concentrations of serum overnight before washing the cells with PBS and cultured in media containing 0.1% serum. The cells were trypsinized, and the ratio of live versus dead cells was determined by trypan blue exclusion assay 0, 6, 12, 24, and 36 h later. By as early as 12 h after culturing in low serum, the TEL-expressing NIH 3T3 cells had a significantly higher percentage of cellular death than control cells or cells expressing the TEL mutant (TEL⌬ETS; see Fig. 1C) .
TEL Impairs the Formation of Focal Adhesions-ETS family members are regulators of ECM remodeling, and TEL influences the expression of several ECM genes including fibronectin and the matrix metalloproteinase Stromelysin-1 (33, 36) . In addition, the cellular aggregation phenotype observed upon TEL expression can be reverted when the cells are cultured on dishes coated with either fibronectin or the extracellular matrix component type IV collagen (33) . Likewise, we have observed that laminin or collagen complements the cell adhesion defect in TEL-expressing Ras transformed cells (data not shown). Given that integrin-mediated signaling is a key apoptotic control pathway (43), we tested whether TEL expression affects the formation of focal adhesions. Monoclonal antibodies directed to the focal adhesion component paxillin (44) were used to detect focal adhesions by immunofluorescence. Paxillin was organized into multiple distinct focal adhesions in control cells ( Fig. 2A, left panel) . By contrast, in the TEL-expressing cells, paxillin was diffusely cytoplasmic with few distinct focal adhesions ( Fig. 2A, right panel) . Therefore, the TEL-mediated reduction in the number of focal adhesions occurs in nontransformed NIH 3T3 cells, which do not aggregate upon TEL expression (36) , and is independent of the general changes in cellular morphology seen in TEL-expressing Ras-transformed NIH 3T3 cells ( Fig. 2A, and data not shown) .
To determine whether the TEL-induced effects on focal adhesion formation were because of a failure to bind to ECM components or because of TEL-mediated repression of a component of focal adhesions or integrin-mediated signaling, we measured focal adhesion formation after culturing the cells on dishes coated with laminin ( Fig. 2A, lower panel) or type IV collagen (data not shown). Providing TEL-expressing cells with laminin or collagen allowed the reformation of distinct focal adhesions either in the absence or presence of oncogenic Ras ( Fig. 2A, right panel, and data not shown) . Thus, the failure to organize focal adhesions is most likely because of the failure to produce an ECM component or the inability to remodel the ECM.
Given the dramatic reduction in the number of focal adhesions in TEL-expressing cells, we tested whether the lack of focal adhesions was responsible for TEL-mediated apoptosis. TEL-expressing cells were plated on dishes coated with type IV collagen, and the growth of these cells was measured after culture in media containing 0.1% serum (Fig. 2B) . Collagen failed to block the increased level of apoptosis observed in the TEL-expressing NIH 3T3 cells. Therefore, TEL-mediated apoptosis appears to be independent of its effects on the formation of focal adhesions or cellular aggregation.
TEL Represses the Bcl-X L Promoter-Given that TEL-induced apoptosis is independent of the state of cellular aggregation and integrin-mediated signaling, we assessed the effects of TEL expression on regulators of apoptosis. Of special interest was the anti-apoptotic Bcl-2 family member Bcl-X L . Stable overexpression of ETS2 in BAC1.2F5 macrophages up-regulates Bcl-X L expression and protects cells from apoptosis induced by removal of survival factors from the growth medium (37) . Transcriptional regulation of Bcl-X is complex with at least three different promoters driving tissue-specific transcription (39, 45) . The translation initiation codon for Bcl-X is located within Exon 2, and transcription initiation can occur close to the start of Exon 2 or from two alternative noncoding Exons 1B or 1A (Fig. 3A) . For the Exon 1A and Exon 2 promoters, most of the regulation was mapped to the region 900 bp upstream of the translational start site (45) . NFB, STATs and ETS factor binding sites identified in this region were demonstrated to regulate transactivation of Bcl-X (37, 46 -48) . Nine potential EBS were identified in the 800 nucleotides 5Ј to the ATG start site of human Bcl-X, and transient expression of ETS2 activated expression of a reporter gene linked to this region by 9-fold (37).
To determine whether TEL can regulate the expression of human Bcl-X we linked either the Exon 1B promoter region (Ϫ2361 to Ϫ1680 from the translational start site) or an 815-bp region upstream of Exon 2 (Ϫ876 to Ϫ61 from the translational start site) to the firefly luciferase gene (Ϫ2361-luc or Ϫ876-luc respectively; see Fig. 3A ). NIH 3T3 cells were transiently transfected with either the Exon 1B promoter region (Ϫ2361-luc) or the Exon 2 promoter region (Ϫ876-luc) and co-transfected with plasmids expressing TEL or empty vector. Although both the Ϫ2361 and Ϫ876 promoters had similar basal activities, NIH 3T3 cells expressing TEL repressed expression of the Ϫ876-luc promoter-linked reporter gene but not the Ϫ2361-luc promoterlinked reporter gene (Fig. 3B) . Thus, TEL-mediated repression of the Bcl-X gene requires sequences located within 900 bp of the translational start site.
Given that the Exon 1A/Exon 2 promoter region contains nine potential EBS, as well as NFB and Stat5 binding sites (Fig. 3A) , we focused on the TEL-mediated repression of this promoter region. TEL expression in NIH 3T3 cells consistently repressed transcription of the Ϫ876-luc promoter, as compared with the inactive TEL⌬ETS (Fig. 3C ), but in some of the experiments the level of repression was modest. TEL is regulated by nuclear export that is dependent on post-translational modification of lysine 99 with a small ubiquitin-like modifier molecule (38, 49) . Thus, a TEL protein in which this lysine is mutated to arginine TEL(K99R) displays enhanced nuclear localization (38) . Therefore, we transiently co-transfected NIH 3T3 cells with Ϫ876-luc and TEL(K99R) and found that whereas TEL repressed the Bcl-X L promoter-linked reporter gene 4-fold, TEL(K99R) repressed transcription even better (9-fold) (Fig. 3C) . This increased level of repression was not because of differences in protein expression as all TEL proteins were expressed to equivalent levels (data not shown).
To determine whether any or all of the previously noted nine potential EBS were important for TEL-mediated repression of the Bcl-X promoter, we made a series of promoter deletions that contained all nine sites, four sites, or one EBS (Ϫ793-luc, Ϫ565-luc, or Ϫ436-luc respectively; see Fig. 3A ). NIH 3T3 cells were transiently transfected with the indicated Bcl-X promoter deletion linked to luciferase and empty vector, TEL, or TEL⌬ETS expression vectors (Fig. 3D) . The Ϫ793-luc reporter gene had decreased basal activity relative to Ϫ876-luc, which may reflect the removal of the NFB activation site. The basal transcriptional activity further diminished with promoter de-
FIG. 2. TEL inhibits focal adhesion formation.
A, coverslips were treated with control (upper panel) or laminin (10 g/ml) overnight and rinsed before NIH 3T3 cells stably infected with empty vector, and TEL were plated in 10% serum overnight. Cells were then fixed in 3.7% formaldehyde solution, extracted in 0.5% Triton X-100 solution, and probed with anti-paxillin monoclonal antibodies. Immunostaining was visualized with rhodamine-conjugated donkey anti-mouse antibodies using epi-fluorescence microscopy. B, NIH 3T3 cells stably infected with vector (Ⅺ) or TEL (E) were plated in 6-well dishes pretreated with either control (Ⅺ, E) or 2 g/cm 2 Collagen IV (f, F) and then grown in 0.1% serum for 36 h. The numbers of live and dead cells were determined using trypan blue exclusion assay at 0, 6, 12, 24, and 36 h. Each data point is the average from triplicate samples, and in some cases the error bars are too small to be seen.
letions Ϫ565-luc and Ϫ436-luc. This decrease may reflect loss of potential activation sites or the loss of the upstream transcriptional start site (Exon 1A). The sequences within the Ϫ436-luc promoter contain a major transcriptional start site and maps to a minimal promoter region originally identified in the mouse bcl-X promoter (45) . In all cases TEL, but not TEL⌬ FIG. 3 . TEL represses the Bcl-X L promoter. A, schematic of the human Bcl-X L promoter region, as well as serial deletions of the promoter linked to the firefly luciferase gene (Ϫ2361-luc, Ϫ876-luc, Ϫ793 luc, Ϫ565 luc, and Ϫ436 luc). The numbers are relative to the translational start site located within Exon 2. There are nine EBS (rectangles), two NFB-like binding sites (ovals), and one STAT-like binding site (triangles) within the promoter. The asterisk (*) denotes transcriptional start sites relative to Exon 1B, Exon 1A, and Exon 2 respectively. B, NIH 3T3 cells were transiently transfected with Ϫ2361-luc or Ϫ876-luc, RSV-Renilla luciferase, and either the empty vector or TEL expression plasmids. After 48 h the luciferase activities were measured, normalized to Renilla luciferase, and plotted as -fold repression. Each experiment was performed in triplicate, and in some cases the error bars are too small to be seen. C, NIH 3T3 cells were transiently transfected with Ϫ876-luc, RSV-Renilla luciferase, and the empty vector, TEL, TEL⌬ETS, or TEL(K99R) expression plasmids. After 48 h the luciferase activities were measured, normalized to Renilla, and plotted as -fold repression. Each experiment was performed in triplicate, and in some cases the error bars are too small to be seen. D, NIH 3T3 cells were transiently transfected with the indicated Bcl-X-luc promoter deletions, RSV-Renilla luciferase, and empty vector, TEL, or TEL⌬ETS expression plasmids. After 48 h the luciferase activities were measured, and the data are plotted as relative light units (RLU) corrected for transfection efficiency by Renilla luciferase expression. Each experiment was performed in triplicate, and in some cases the error bars are too small to be seen. ETS, significantly repressed the transcription from each Bcl-X promoter deletion-driven reporter gene.
Although the Ϫ436-luc promoter construct contains only one of the previously noted EBS (37) , it contains an additional 16 GGA motifs, which comprises the core ETS factor consensus sequence. Rather than attempt to individually mutate each of the 17 GGA sequences within the minimal Bcl-X promoter, we used chromatin immunoprecipitation assays to determine whether TEL associates with Bcl-X in vivo. The 5Ј regulatory regions of the human and murine Bcl-X gene are highly homologous. All nine previously noted EBS within Exon 1A/Exon 2 promoter regions are conserved, and the murine sequence contains two additional potential EBS (37) . NIH 3T3 cells express detectable amounts of endogenous TEL; therefore we used this system to determine whether TEL associates with the sequences just 5Ј to the transcriptional start site located within Exon 2 of Bcl-X. NIH 3T3 cells were cross-linked with formaldehyde, the cells were lysed, and the chromatin was sheared to yield genomic fragments between 500 and 1000 bp prior to immunoprecipitation with an antibody directed against the N terminus of TEL. PCR primers were designed to amplify the minimal Bcl-X promoter surrounding the EBS nearest to the Exon 2 transcriptional start site, to encompass the other eight EBS, as well as the promoter upstream of Exon 1B (see Fig. 3A and Fig. 4A ). In principle, these primers could amplify TELassociated genomic sequences within 1000 bp upstream or downstream of the distal primer sequence. Primers designed to detect an irrelevant gene (ETO2), as well as to detect a region 50-kbp downstream of the minimal promoter region (within Exon 3 of Bcl-X), were used as specificity controls (Fig. 4A) . Amplification of the Bcl-X 1B promoter region was inconsistent, but in some experiments it was detected as slightly above background (data not shown). The lack of TEL-mediated repression of the Ϫ2361-luc promoter is consistent with little or no binding of TEL to the sequences upstream of Exon 1B. However, the regions containing EBSs 1-8, as well as EBS 9 upstream of the Exon 2, were specifically detected with the N-terminal TEL antiserum but not with anti-HA or anti-Gal4 antibodies (Fig. 4, B and C) . The Bcl-X L promoter region with the EBS adjacent to Exon 2 (Ϫ142 nt relative to the translational start site) displayed the strongest association with TEL of the promoter regions analyzed, which is consistent with the ability of TEL to repress this promoter (see Fig. 3D and Fig.  4B ). In addition, the PCR performed with samples immunoprecipitated with the N-terminal TEL antibody failed to amplify either the Exon 3 coding region of Bcl-X L or intronic sequences from ETO2 (Fig. 4, B and C) .
TEL Represses the Expression of Endogenous Bcl-X L -Given the fact that TEL represses an artificial Bcl-X L promoter and binds to the endogenous promoter, we assessed the ability of TEL to affect the expression of endogenous Bcl-X L . Total RNA was isolated from NIH 3T3 cells stably infected with control retrovirus or retrovirus expressing either TEL or TEL⌬ETS. The RNA was analyzed by Northern blot with a Bcl-X L -specific probe, as well as a GAPDH-specific probe as a loading control. Bcl-X L mRNA was significantly down-regulated in NIH 3T3 cells expressing TEL but not TEL⌬ETS (Fig. 5A) . This downregulation of Bcl-X L mRNA was reflected in the levels of Bcl-X L protein expressed. The TEL-expressing NIH 3T3 cells contained 2-4-fold less Bcl-X L in comparison with controls (Fig.  5B ). This decrease in Bcl-X L protein does not reflect an alteration in Bcl-X splicing given that we did not detect expression of Bcl-X S protein in the samples. This level of Bcl-X L protein down-regulation was similar whether the cells were grown in 10% serum, 0.1% serum, or on plates coated with type IV collagen (Fig. 5C , and data not shown). Furthermore, this down-regulation was specific to Bcl-X L , as we observed no alteration in the levels of other BCL2 family members, including Bcl-2 or Bax (data not shown). Thus, the change in the ratio of Bcl-X L to pro-apoptotic molecules may contribute to the apoptosis induced by TEL (Fig. 1) .
Next, we set out to determine the relationship between Bcl-X L and TEL-induced apoptosis. TEL-expressing NIH 3T3 cells were infected with a control or a Bcl-X L -expressing retrovirus and cultured in media containing 0.1% serum. Although the enforced expression of Bcl-X L protected the cells from TELinduced apoptosis, the level of Bcl-X L expressed was at least 5-fold higher than endogenous levels (data not shown). Therefore, we asked whether a reduction of Bcl-X L protein was sufficient to alter cell viability. We selected immortalized 3T3 cells from mouse embryos with wild-type Bcl-X or a targeted disruption of one or both alleles of Bcl-X (40). As expected, the level of Bcl-X L protein was reduced in the heterozygous cells and ab- FIG. 5 . TEL represses Bcl-x L mRNA and protein expression. A, total cellular RNA was isolated from NIH 3T3 cells stably infected with empty vector, TEL, or TEL⌬ETS and separated on 2.5 M formaldehyde-1% agarose gel. The RNA was transferred to a nylon membrane and probed with radiolabeled Bcl-X L -and GAPDH-specific cDNA probes. B, 100 g of detergent-soluble proteins from NIH 3T3 cells stably infected with empty vector, TEL, or TEL⌬ETS were separated by SDS-PAGE and immunoblotted with Bcl-X L/S -and actin-specific antisera. C, 100 g of detergent-soluble proteins from NIH 3T3 cells stably infected with empty vector, TEL, or TEL⌬ETS grown overnight on either control plates or collagen type IV (2 g/cm 2 )-coated plates were separated by SDS-PAGE and immunoblotted with Bcl-X L/S -and actinspecific antisera.
FIG. 6. Loss of Bcl-X promotes apoptosis.
A, 100 g of detergentsoluble proteins from 3T3 cells derived from wild-type, heterozygous, or null Bcl-X targeted mice (WT, HET, and NULL, respectively) were separated by SDS-PAGE and immunoblotted with Bcl-X L/S -and GAPDH-specific antisera. B, 3T3 cells derived from wild-type, heterozygous, or null Bcl-X targeted mice (WT, Ⅺ; Het, छ; or Null, E) were grown in 0.1% serum for 48 h. The numbers of live and dead cells were determined using the trypan blue exclusion assay at 0, 12, 24, and 48 h. Each data point is the average from triplicate samples, and in some cases the error bars are too small to be seen. C, Bcl-X-null 3T3 cells stably infected with empty vector (Ⅺ) or TEL WT (छ) were grown in 0.1% serum for 48 h. The numbers of live and dead cells were determined using trypan blue exclusion at 0, 12, 24, and 48 h. Each data point is the average from triplicate samples, and in some cases the error bars are too small to be seen. sent in the Bcl-X-null cells (Fig 6A) . When these cells were cultured in media containing low serum, the Bcl-X-null cells displayed a higher percentage of cell death than wild-type cells, and the heterozygous cells exhibited an intermediate level of cell death (Fig. 6B) . Thus, a modest reduction in the levels of Bcl-X L protein is sufficient to sensitize cells to apoptosis. In addition, when TEL was expressed in the Bcl-X-null cells, it did not further enhance apoptosis (Fig. 6C) , suggesting that either the cellular rate of apoptosis is maximal in these cells or that the TEL-induced apoptosis response works through a Bcl-X Ldependent pathway. DISCUSSION TEL is an inhibitor of growth in a number of transformed cell types including Ras-transformed NIH 3T3 cells and selected "permissive" NIH 3T3 cells that may be partially transformed (34, 36) . Although we did not observe any reproducible change in cell cycle progression upon TEL expression in NIH 3T3 cells either in the absence or presence of activated Ras (data not shown), TEL expression caused a small change in the number of cells accumulating in the G 1 phase of the cell cycle in permissive NIH 3T3 cells (34) . We observed that TEL expression increased the level of apoptosis, rather than affecting cell cycle progression. Although TEL-induced apoptosis was observed in the presence of 10% calf serum when NIH 3T3 cells were first infected, the level of apoptosis diminished with time in culture. However, the apoptosis was more dramatic and consistent when the cells were cultured in medium containing low concentrations of serum (Fig. 1) .
The modest level of apoptosis that is triggered by the expression of oncogenes or tumor suppressors is often difficult to capture in the presence of growth factors, either because of their survival functions that suppress apoptosis or because of the rapid growth of cells not undergoing apoptosis. For instance, c-Myc is a potent trigger for apoptosis, but this phenotype is most clearly observed when cells are grown in low serum or when survival factors are removed from the culture medium (50) . Although c-Myc-induced apoptosis can be mediated by induction of the p19 ARF /p53 tumor suppressor pathway, c-Myc expression also causes a drop in Bcl-X L expression (51). This repression was not because of c-Myc directly repressing Bcl-X L transcription but appears to be an indirect response of the cell to the expression of a potent stimulator of cell cycle progression.
Subtle changes in the cellular levels of Bcl-X L expression can have dramatic phenotypes. For example, 2-4-fold reduction in the expression of Bcl-X L is sufficient to induce apoptosis following withdrawal of thrombopoietin from UT-7/thrombopoietin and normal megakaryocytic cells (52) . Similarly, a 2-fold change in Bcl-X L protein was related to a 10% increase in apoptosis of normal megakaryocytic cells 24 h after thrombopoietin withdrawal (52) . We found that cells lacking one allele of Bcl-X L , with a concomitant 50% reduction in protein expression, displayed increased apoptosis when cultured in medium containing low serum (Fig. 6, A and B) . The changes in Bcl-X L levels and apoptosis were similar to those that we observed following expression of TEL. Conversely, overexpression of ETS2 in BAC1.2F5 macrophages protected these cells from apoptosis induced upon withdrawal of colony-stimulating factor-1, even though Bcl-X L mRNA levels increased only 4-fold (37) . Thus, the level of repression of Bcl-X L that we observed upon TEL overexpression (Fig. 5) is likely sufficient to contribute to apoptosis upon withdrawal of survival factors where the scales are tipped to a pro-apoptotic versus an anti-apoptotic response.
Although TEL-mediated repression of Bcl-X L likely contributes to TEL-induced apoptosis, the repression of other genes may also contribute to apoptosis. The regulation of the stromelysin gene is critical for tissue homeostasis. Repression of Stromelysin-1 and other extracellular matrix components likely regulates the alterations in cellular morphology and cell adhesion observed when TEL is expressed in transformed or partially transformed fibroblasts. However, the changes in cell adhesion appear unlinked to TEL-induced alterations in focal adhesions, because TEL expression affects the formation of focal adhesions in the absence of changes in cellular morphology (Fig. 2) . Also, collagen complemented adhesion phenotype but did not dramatically affect TEL-induced apoptosis (Fig.  2B) . Therefore, if the changes in the numbers of focal adhesions or alterations in cell adhesion contribute to TEL-mediated apoptosis, the effect is subtle and was not observed in our assays.
Bcl-X L is an important integrator of diverse signaling pathways mediating cellular survival and death. These signaling cascades activate multiple transcription factors including NFB, STAT5, ETS1, and ETS2, which in turn activate Bcl-X L to promote cell survival (46 -48) . These signaling events are critical to disease processes including chronic myeloid leukemia in which the BCR-ABL fusion protein inappropriately activates STAT5 to induce Bcl-X L expression and increase cellular survival (53) (54) (55) . Additionally, three fusion proteins involving TEL (TEL-platelet-derived growth factor receptor, TEL-JAK2, and TEL-ABL) strongly induce activation of STAT5 (56, 57) . Although the ability of TEL-platelet-derived growth factor receptor ␤, TEL-JAK2, or TEL-ABL to regulate Bcl-X L expression has not been established, all of these fusion proteins are sufficient for transformation of hematopoietic cells. Based on our data we speculate that the loss of one TEL allele through translocation may cooperate with the tyrosine kinase-mediated activation of STAT signaling and contribute to activation of Bcl-X L .
In contrast to the above fusion proteins, expression of TEL/ AML1 is not sufficient for inducing transformation and appears to require additional mutations (58) . Given that both alleles of TEL are disrupted in up to 90% of t(12;21)-containing cases of B-cell acute lymphoblastic leukemia, it is possible that loss of TEL contributes to cell survival. Consistent with this interpretation, we have found that Bcl-X L is slightly higher in t(12;21)-containing cases of B-cell acute lymphoblastic leukemia. 2 However, loss of TEL would be predicted to only de-repress and allow activation by other transcription factors, and we have not been able to mechanistically link this small (2-fold) increase in Bcl-X L levels to loss of TEL. In this regard, the t(12;22) fusion protein would be predicted to stimulate Bcl-X L expression as it contains the DNA binding domain of TEL but activates rather than represses transcription (6). Thus, it is possible that reversing TEL-mediated repression of Bcl-X L contributes to t(12; 22)-mediated leukemogenesis.
